ALAMEDA, Calif., April 25, 2023 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the following investor conferences on the dates and times listed below:
Event: | Bank of America Securities 2023 Health Care Conference |
Date: | Tuesday, May 9, 2023 |
Time: | 1:40pm ET / 10:40am PT |
Event: | 2023 RBC Capital Markets Global Healthcare Conference |
Date: | Tuesday, May 16, 2023 |
Time: | 11:30am ET / 8:30am PT |
Webcasts of the presentations will be available by visiting the investors' section of the company's website at www.penumbrainc.com. The webcasts will be available on the company's website for at least two weeks following the event.
About Penumbra
Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets novel products and has a broad portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra supports healthcare providers, hospitals and clinics in more than 100 countries. For more information, visit www.penumbrainc.com and connect on Twitter and LinkedIn.
Investor Relations
Penumbra, Inc.
510-995-2461
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$277.35 |
| Daily Change: | -0.44 -0.16 |
| Daily Volume: | 319,885 |
| Market Cap: | US$10.640B |
February 18, 2025 December 30, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
